Viking Therapeutics closes upsized offerings: 9.04m shares at $35 and $258.75m of 2.00% convertible notes due 2032

Viking Therapeutics closed concurrent upsized public offerings of 9,035,714 common shares at $35.00 per share and $258.75 million aggregate principal of 2.00% convertible senior notes due 2032, including full exercise of underwriters' options.

Detected & updated continuously · Source: Nebula